P3, N=586, Recruiting, University of Birmingham | Trial completion date: Feb 2028 --> Apr 2030 | Trial primary completion date: Aug 2026 --> Oct 2028

P3, N=619, Active, not recruiting, Incyte Corporation | Recruiting --> Active, not recruiting

P=N/A, N=150, Completed, AbbVie | Recruiting --> Completed

Next, we used clinically available signal inhibitors (MEK inhibitor trametinib, JAK inhibitor ruxolitinib, and JNK inhibitor SP600125), and found that ruxolitinib inhibits AMIGO2 expression more stably. Using the MKN45 gastric cancer cells, we confirmed that ruxolitinib could prevent liver metastasis of human cancer cells. These results demonstrate that pharmacological inhibition of AMIGO2 expression in tumor cells is a promising novel strategy to prevent and control liver metastasis.

These novel time-dependent transfusion burden analyses demonstrate that momelotinib is associated with anemia-related benefits in most patients and greater transfusion burden reduction versus comparators.

Of these, 29% did not have features consistent with anti-MDA5 disease. However, when present, MDA5 disease is severe with a high mortality.

P1/2, N=30, Not yet recruiting, Shanghai Chest Hospital

P1, N=12, Not yet recruiting, Beijing Tiantan Hospital

Upadacitinib efficacy, including very low rates of radiographic progression, was demonstrated through 104 weeks in treatment-refractory patients with active AS. Treatment was well tolerated, with no newly identified safety signals.

P4, N=100, Recruiting, Incyte Corporation | Trial completion date: Sep 2024 --> Feb 2025 | Trial primary completion date: Sep 2024 --> Feb 2025

P1/2, N=23, Active, not recruiting, University of Pennsylvania | Trial primary completion date: Oct 2024 --> May 2024

P4, N=308, Not yet recruiting, University Hospital, Toulouse

P1, N=28, Completed, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting --> Completed | N=73 --> 28 | Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Jul 2024 --> Sep 2024

P1, N=10, Not yet recruiting, Northwestern University

P1, N=40, Recruiting, Icahn School of Medicine at Mount Sinai | Trial completion date: Oct 2024 --> Jun 2025 | Trial primary completion date: Oct 2024 --> Jun 2025

P=N/A, N=10, Not yet recruiting, Peking University Hospital of Stomatology; Peking University Hospital of Stomatology

P=N/A, N=28, Not yet recruiting, The First Affiliated Hospital, School of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University

P=N/A, N=200, Not yet recruiting, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College; Hospital for Skin Diseases

P4, N=300, Not yet recruiting, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

P2, N=82, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2024 --> Nov 2025

P2, N=120, Recruiting, VivaVision Biotech, Inc

P3, N=204, Active, not recruiting, Incyte Corporation | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Aug 2025

P2, N=102, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Trial primary completion date: Jun 2024 --> Oct 2024

P2, N=40, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Trial primary completion date: Jun 2024 --> Oct 2024

P1, N=476, Completed, Taro Pharmaceuticals USA

P2, N=41, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Jan 2025 --> Dec 2026 | Trial primary completion date: Jan 2025 --> Dec 2025

In concordance with studies of background risk, AEs were more common in patients with CV risk enrichment, particularly those aged ≥ 65 years. Tofacitinib effectiveness/persistence were generally similar regardless of CV risk enrichment. These findings support individualised treatment benefit-risk assessment, including CV assessment/management, to optimise RA outcomes.

P=N/A, N=112, Terminated, Pfizer | N=750 --> 112 | Trial completion date: Apr 2028 --> Jul 2024 | Recruiting --> Terminated | Trial primary completion date: May 2027 --> Jul 2024; Business decision: Due to the slow recruitment, the sponsor decided to discontinue the study early.

Our findings suggest that tofacitinib may reduce the risk of all-cause mortality in patients with anti-MDA5 antibody-positive DM-ILD without an increased risk of additional infections. PROSPERO: CRD42023445427; https://www.crd.york.ac.uk/prospero/.

P2, N=0, Withdrawn, Douglas Johnson | N=25 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Apr 2026 --> Sep 2026

P2, N=16, Terminated, University of California, San Francisco | Completed --> Terminated; Low accrual

P2, N=28, Recruiting, Jonathan Brammer | Trial primary completion date: Dec 2024 --> Dec 2025

P3, N=134, Not yet recruiting, McMaster University

P2, N=120, Not yet recruiting, H. Lee Moffitt Cancer Center and Research Institute

P3, N=843, Completed, Astellas Pharma Inc | Phase classification: P2b --> P3

Our results revealed the relationships among the ERα, PI3K/AKT, and MAPK signaling pathways in ER+ breast cancer cells. Understanding the interactions among ERα, PI3K-AKT-mTOR, and MAPK could lead to novel combination therapies.

Case Report: Here, we describe a case in which upadacitinib, a JAK1-selective inhibitor, was used to manage a severe RA flare-up occurring during ICI therapy with pembrolizumab, an anti-programmed cell death protein-1 antibody. We did not observe recurrence of lung cancer for more than 1 year during upadacitinib therapy. Upadacitinib could be a safe and effective option to treat severe RA flare-ups occurring during anti-PD-1 ICI therapy.

With respect to immunosuppressive treatment used to control RA, it was observed that glucocorticoids (especially high-dose usage) and Rituximab (RTX) predispose the patients to poor SARS-CoV-2 outcomes, as opposed to Baricitinib and interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) inhibitors. COVID-19 vaccination has proven effective and generally safe for RA patients in some studies, although therapies with Methotrexate (MTX), Abatacept (ABA), and RTX have been associated with impaired vaccine immune response. This systematic literature review brings updated and thorough information with respect to the immunological, clinical, and management of a complex immune-mediated inflammatory disease (IMID) like RA in the setting of COVID-19 and underlines the challenges faced by this group of patients. The lessons learned can be extended beyond the pandemic in shaping a more informed and compassionate healthcare system and offering long-term medical care for patients with RA.

P1/2, N=147, Active, not recruiting, NRG Oncology | Trial completion date: Sep 2022 --> Aug 2025

P3, N=300, Recruiting, Priovant Therapeutics, Inc. | Not yet recruiting --> Recruiting | N=220 --> 300 | Trial completion date: Aug 2027 --> Feb 2028

Furthermore, the elevated production of inflammatory cytokines observed in 3CK-treated hiPSC-COs was attenuated by treatment with tofacitinib. Our UC model will be an essential tool to understand its pathologic mechanisms and identify effective therapeutic approaches.

P3, N=0, Withdrawn, Vanderbilt University Medical Center | N=550 --> 0 | Not yet recruiting --> Withdrawn